Breaking News Instant updates and real-time market news.

ASND

Ascendis Pharma

$76.21

0.86 (1.14%)

16:07
08/29/18
08/29
16:07
08/29/18
16:07

Ascendis Pharma reports Q2 EPS EUR (.55) vs. EUR (.94) in Q217

For the second quarter, Ascendis Pharma reported a net loss of EURO$22.8M, or EURO$0.55 per share compared to a net loss of EURO$30.7M, or EURO$0.94 per share for the same period in 2017. As of June 30, 2018, the company had cash and cash equivalents of EURO$352.6M compared to EURO$348.4M as of March 31, 2018. As of June 30, 2018, Ascendis had 41,841,590 ordinary shares outstanding."We continue to execute on our strategic goals, advancing towards our vision to build a fully integrated biopharma company," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "We intend to provide sustainable growth from multiple sources, both from our three independent rare disease endocrinology product opportunities, and by applying our TransCon technology platform in new therapeutic areas. Our proprietary platform technologies and our mindset for innovation are the foundations of this ability to develop differentiated products that address major unmet medical needs."

  • 29

    Aug

  • 05

    Sep

  • 12

    Sep

ASND Ascendis Pharma
$76.21

0.86 (1.14%)

03/21/18
JPMS
03/21/18
NO CHANGE
Target $75
JPMS
Overweight
Ascendis Pharma price target raised to $75 from $60 at JPMorgan
JPMorgan analyst Jessica Fye raised her price target for Ascendis Pharma to $75 saying she remains "very positive" following the company's ENDO 2018 data presentations for both the TransCon hGH and PTH programs. The analyst believes Ascendis is in the midst of a transformation to a company with multiple orphan endocrine assets in human testing, and ultimately a platform story. She sees a high probability of success for the Phase III trial evaluating TransCon Growth Hormone for pediatric growth hormone deficiency. Fye keeps an Overweight rating on Ascendis Pharma.
05/14/18
JPMS
05/14/18
NO CHANGE
Target $79
JPMS
Overweight
Ascendis Pharma added to Analyst Focus List at JPMorgan
JPMorgan analyst Jessica Fye added Ascendis Pharma to the firm's Analyst Focus List, citing confidence in the company's "consistent clinical and preclinical data" across its orphan endocrinology pipeline. Fye sees Ascendis transitioning from being viewed as a single product company to one with multiple orphan endocrine assets in the clinic and a platform story. The analyst, who sees a high probability of success for the company's lead asset TransCon hGH, reiterates her Overweight rating and raised her price target on Ascendis shares to $79 from $75.
05/31/18
LEER
05/31/18
NO CHANGE
Target $70
LEER
Market Perform
Ascendis Pharma price target raised to $70 from $64 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Ascendis Pharma to $70 from $64 following quarterly results. The analyst reiterates a Market Perform rating on the shares.
06/26/18
STFL
06/26/18
INITIATION
Target $85
STFL
Buy
Ascendis Pharma initiated with a Buy at Stifel
Stifel analyst Adam Walsh initiated Ascendis Pharma with a Buy rating and $85 price target, stating that he sees the company's TransCon technology having "game-changing" potential to fix the pharmacokinetic and related clinical shortcomings of both currently approved drugs as well as those in development.

TODAY'S FREE FLY STORIES

MU

Micron

$46.06

1.01 (2.24%)

16:52
09/20/18
09/20
16:52
09/20/18
16:52
Hot Stocks
Micron says it achieved record revenue in FY18 »

Says expects 1ynm sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

PMBC

Pacific Mercantile Bancorp

$9.75

0.025 (0.26%)

16:50
09/20/18
09/20
16:50
09/20/18
16:50
Hot Stocks
Breaking Hot Stocks news story on Pacific Mercantile Bancorp »

EJF Capital reports 7.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

MU

Micron

$46.06

1.01 (2.24%)

16:46
09/20/18
09/20
16:46
09/20/18
16:46
Hot Stocks
Breaking Hot Stocks news story on Micron »

Micron up 5.7% to $48.69…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

BHBK

Blue Hills Bancorp

$23.55

0.4 (1.73%)

16:45
09/20/18
09/20
16:45
09/20/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Blue Hills Bancorp »

Blue Hills Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$24.82

0.17 (0.69%)

16:44
09/20/18
09/20
16:44
09/20/18
16:44
Initiation
Teva initiated  »

Teva assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CRSP

Crispr Therapeutics

$48.90

-3 (-5.78%)

16:44
09/20/18
09/20
16:44
09/20/18
16:44
Initiation
Crispr Therapeutics initiated  »

Crispr Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 21

    Sep

NTLA

Intellia Therapeutics

$31.50

-0.48 (-1.50%)

16:44
09/20/18
09/20
16:44
09/20/18
16:44
Initiation
Intellia Therapeutics initiated  »

Intellia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

EDIT

Editas Medicine

$32.55

-0.64 (-1.93%)

16:43
09/20/18
09/20
16:43
09/20/18
16:43
Initiation
Editas Medicine initiated  »

Editas Medicine initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMC

Western Asset Mortgage

$11.30

0.055 (0.49%)

16:42
09/20/18
09/20
16:42
09/20/18
16:42
Syndicate
Western Asset Mortgage 6.5M share Spot Secondary; price range $10.85-$11.10 »

Morgan Stanley,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda Pharmaceuticals

$20.00

0.4 (2.04%)

16:41
09/20/18
09/20
16:41
09/20/18
16:41
Initiation
Vanda Pharmaceuticals initiated  »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

WYNN

Wynn Resorts

$137.32

1.64 (1.21%)

16:41
09/20/18
09/20
16:41
09/20/18
16:41
Hot Stocks
Breaking Hot Stocks news story on Wynn Resorts »

Lone Pine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$66.83

0.57 (0.86%)

, RDS.B

Royal Dutch Shell

$68.85

0.56 (0.82%)

16:41
09/20/18
09/20
16:41
09/20/18
16:41
Periodicals
Shell in discussions to sell $1.3B in Gulf Coast assets, Bloomberg says »

Royal Dutch Shell is in…

RDS.A

Royal Dutch Shell

$66.83

0.57 (0.86%)

RDS.B

Royal Dutch Shell

$68.85

0.56 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPVG

TriplePoint Venture

$12.97

-0.01 (-0.08%)

16:39
09/20/18
09/20
16:39
09/20/18
16:39
Initiation
TriplePoint Venture initiated  »

TriplePoint Venture…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$4.70

-0.25 (-5.05%)

16:38
09/20/18
09/20
16:38
09/20/18
16:38
Initiation
KemPharm initiated  »

KemPharm assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLL

Ball Corp.

$44.39

0.15 (0.34%)

16:35
09/20/18
09/20
16:35
09/20/18
16:35
Hot Stocks
Ball Corp. CFO Scott Morrison sells over $1M in company shares »

Ball Corp. CFO Scott…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLIT

Harmonic

$5.20

0.15 (2.97%)

16:34
09/20/18
09/20
16:34
09/20/18
16:34
Initiation
Harmonic initiated  »

Harmonic initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

WMC

Western Asset Mortgage

$11.30

0.055 (0.49%)

16:34
09/20/18
09/20
16:34
09/20/18
16:34
Syndicate
Western Asset Mortgage files to sell 6.5M shares of common stock »

Morgan Stanley, BofA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,944.26

17.99 (0.93%)

, AAPL

Apple

$220.00

1.655 (0.76%)

16:33
09/20/18
09/20
16:33
09/20/18
16:33
Periodicals
Twitch appears to be blocked in China, Abacus reports »

Amazon's (AMZN)…

AMZN

Amazon.com

$1,944.26

17.99 (0.93%)

AAPL

Apple

$220.00

1.655 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WMC

Western Asset Mortgage

$11.30

0.055 (0.49%)

16:32
09/20/18
09/20
16:32
09/20/18
16:32
Syndicate
Western Asset Mortgage files to sell 6.5M shares of common stock »

Morgan Stanley, BofA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$70.79

0.8 (1.14%)

16:32
09/20/18
09/20
16:32
09/20/18
16:32
Hot Stocks
Merck receives positive CHMP opinion for DELSTRIGO and PILFETRO in E.U. »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 23

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

16:30
09/20/18
09/20
16:30
09/20/18
16:30
Options
Preliminary option volume of 24.2M today »

Preliminary option volume…

INDB

Independent Bank

$89.85

0.65 (0.73%)

, BHBK

Blue Hills Bancorp

$23.55

0.4 (1.73%)

16:29
09/20/18
09/20
16:29
09/20/18
16:29
Hot Stocks
Independent Bank to acquire Blue Hills Bancorp »

Independent Bank (INDB),…

INDB

Independent Bank

$89.85

0.65 (0.73%)

BHBK

Blue Hills Bancorp

$23.55

0.4 (1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTV

Veritiv

$44.70

-0.65 (-1.43%)

16:29
09/20/18
09/20
16:29
09/20/18
16:29
Syndicate
Veritiv files to sell 1.5M shares of common stock for holders »

Morgan Stanley is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTV

Veritiv

$44.70

-0.65 (-1.43%)

16:29
09/20/18
09/20
16:29
09/20/18
16:29
Syndicate
Veritiv files to sell 1.5M shares of common stock for UWW Holdings, LLC »

Morgan Stanley & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FATE

Fate Therapeutics

$14.02

0.67 (5.02%)

16:26
09/20/18
09/20
16:26
09/20/18
16:26
Syndicate
Fate Therapeutics $100M Spot Secondary; re-offered at $13.50 »

Jefferies, Piper Jaffray…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.